Olema Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application for OP-3136, a novel small molecule that potently and selectively inhibits KAT6, a validated epigenetic target that is dysregulated in breast and other cancers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals Secures Major Partnership and Funding
- Olema Oncology up 13% at $11.40 after entering supply pact with Novartis
- Olema Oncology, Novartis enter clinical trial collaboration and supply agreement
- Olema Oncology reports Q3 EPS (60c), consensus (58c)
- OLMA Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com